SFDA nod marks company’s strategic entry into high-value specialty oncology injectables as it targets expanding stem cell transplant and haemato-oncology market in the GCC region
The approved product has an estimated market size of around US$ 210 million for the twelve months ending May 2023
The drugmaker's net profit slipped 26 per cent on-year to Rs 143.8 crore
It adds Rezurock (belumosudil) an FDA-approved, first-in-class treatment for adult and pediatric patients 12 years and older with chronic graft-versus-host disease (cGVHD)
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
